Form 4 Absci Corp For: 6 July
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Absci Corp (ABSI)
The Absci share price today is 11.395, view NASDAQ ABSI stock exchange data. Track the latest Absci share price with real-time updates on ABSI stock performance including market cap, day range, 52-week range and dividend yield. Access ABSI charts, earnings dates and analyst estimates to support your investment decisions.
11.400
-0.140(-1.21%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.270
12.000
52 wk Range
2.240
12.055
ABSI is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.27012.000
52 wk Range
2.24012.055
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABSI Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
13.000
Upside
+14.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Absci director Mary T Szela buys $148,866 in stock
- Investing.com
- Form 4 Absci Corp For: 26 June
- Investing.com
- Form 4 Absci Corp For: 6 July
- Investing.com
- Absci director Mary T Szela buys $148,866 in stock
- Investing.com
- Absci receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.000
(+14.04% Upside)
Absci Corp Earnings Call Summary for Q1/2026
- Absci posted Q1 2026 revenue of $215K, missing forecast of $1.43M by 85%; EPS of -$0.19 beat estimate of -$0.1943 by 2.21%
- R&D expenses rose 17.7% YoY to $19.3M; company maintains $125.7M cash position, sufficient to fund operations into H1 2028
- Stock declined 0.84% after-hours to $5.90 but rebounded 1.53% in premarket; trades near 52-week high with 115% annual return
- ABS-201 program for androgenetic alopecia targets interim proof-of-concept data in H2 2026, full results expected early 2027
- Management pursuing strategic pharma partnerships for non-dilutive funding; analysts maintain Buy rating with price targets of $4.20-$12.00
Last Updated: 11-05-2026, 09:26 pm
Read Full TranscriptEarnings
Latest Release
07-05-2026
EPS / Forecast
-0.19 / -0.19
Revenue / Forecast
215K / 1.43M
Compare ABSI to Peers and Sector
Metrics to compare | ABSI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABSIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.5x | −4.3x | −0.4x | |
PEG Ratio | −1.53 | −0.09 | 0.00 | |
Price/Book | 11.4x | 2.3x | 2.6x | |
Price / LTM Sales | 1,064.7x | 100.5x | 3.1x | |
Upside (Analyst Target) | 12.7% | 123.9% | 48.3% | |
Fair Value Upside | Unlock | −0.1% | 6.1% | Unlock |
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Absci (ABSI) Share Price Today?
The Absci share price today is 11.400.
What is the current Absci (ABSI) share price and day range?
As of 07-07-2026, the Absci share price is 11.400, with a previous close of 11.540. The share price has ranged from 11.270 to 12.000 today, while the 52-week range spans from 2.240 to 12.055.
What Is the Absci Market Cap?
As of today, Absci market cap is 1.950B.
What Is the Absci (ABSI) Share Price Target?
The average 12-month share price target for Absci is 13.000, with a high estimate of 17 and a low estimate of 7. 10 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +14.04% Upside potential.
What Is Absci's Earnings Per Share (TTM)?
The Absci EPS (TTM) is -0.823.
When Is the Next Absci Earnings Date?
Absci will release its next earnings report on 18-08-2026.
From a Technical Analysis Perspective, Is ABSI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Absci Trade On?
Absci is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Absci?
The stock symbol for Absci is "ABSI."
How Many Times Has Absci Stock Split?
Absci has split 0 times.
How Many Employees Does Absci Have?
Absci has 140 employees.
What Is the ABSI Premarket Price?
ABSI's last pre-market stock price is 11.880. The pre-market share volume is 78,580.000, and the stock has changed by 0.340, or 2.950%.
What Is the ABSI After Hours Price?
ABSI's last after hours stock price is 11.550, the stock has changed by 0.010, or 0.090%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.